Geovax Labs (GOVX) Stock Price, Quote & News

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell c...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 384 7220

Website: www.geovax.com

Address:

1955 Lake Park Drive, Suite 380, Smyrna, United States

reversal_trades Aug. 19 at 5:11 PM

$EVAX everyone sleeping? EVAX has cancer vaccine and has Merck partnership + low float. Could get an overnight rip potentially. It is the closest sympathy it seems. When they realize..... $MRNA in the news globally and short squeeze $ARCT $GOVX

1 · Reply

PennySearch Aug. 19 at 2:38 PM

⏱️ One-Hour Volume Alert Update $FEMY near $2.68 • 25.68x RVOL Day Range: $2.53 - $3.69 $GOVX near $0.63 • 18.62x RVOL Day Range: $0.59 - $0.66 $TGL near $3.04 • 13.39x RVOL Day Range: $2.71 - $3.29 Unusual volume does not guarantee direction—it highlights attention. Not financial advice.

0 · Reply

johnrivers0110 Aug. 19 at 2:12 PM

$CISS $GOVX $VRAX $MRNA $YJ Shorts are loading 🔺 especially on options stock mrna Trust me 🪡🪡🪡🩸🩸🩸 The FiB 🔺

1 · Reply

danceraka Aug. 19 at 2:05 PM

$CISS top watch, could go 10$-20$ like $PFSA $MRNA $FEMY $GOVX

0 · Reply

PennySearch Aug. 19 at 1:38 PM

📊 Today's Highest Relative Volume $FEMY — 24.65x RVOL Move: +61% Volume: 15.8M (640.1K average) Market Cap: $10.2M $TGL — 20.39x RVOL Move: +3% Volume: 4.2M (207.8K average) Market Cap: $5.4M $GOVX — 18.16x RVOL Move: -3% Volume: 10.4M (571.5K average) Market Cap: $4.6M High relative volume highlights where market attention is concentrated. Which one are you watching? 👀 Not financial advice.

0 · Reply

danceraka Aug. 19 at 1:26 PM

$CISS $FEMY $GOVX $VRAX

0 · Reply

CoffeeRocks Aug. 19 at 1:18 PM

$CODX $GOVX $VRAX $ISPC $MRNA Bio sector hot hot hot

0 · Reply

johnrivers0110 Aug. 19 at 1:01 PM

$CISS $GOVX $VRAX $MRNA $YJ

1 · Reply

RiseAboveAll752 Aug. 19 at 12:58 PM

$GOVX probably goes green

0 · Reply

RiseAboveAll752 Aug. 19 at 12:49 PM

$GOVX any reason?

0 · Reply

GeoVax Labs Slides: Corporate presentation

Jul 27, 2026, 4:00 PM EDT - 22 days ago

GeoVax Labs Earnings release: Q2 2026

Jul 27, 2026, 4:00 PM EDT - 22 days ago

GeoVax Labs Quarterly report: Q2 2026

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

GeoVax Labs Slides: Corporate presentation

May 28, 2026, 11:00 AM EDT - 2 months ago

GeoVax Labs Transcript: Investor update

2026-05-26T16:25:42.000Z - 3 months ago

GeoVax Labs discontinues development of COVID-19 vaccine candidate

2026-05-26T16:24:55.000Z - 3 months ago

Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development

2026-05-26T14:06:13.000Z - 3 months ago

GeoVax Labs files to sell 7.64M shares of common stock for holders

May 26, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Registration statement: Registration filing

2026-05-19T16:21:43.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/19/26

AIIO SBFM

May 18, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Proxy statement: Proxy filing

May 14, 2026, 7:00 AM EDT - 3 months ago

GeoVax Labs Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

GeoVax Labs Earnings release: Q1 2026

May 8, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

GeoVax Labs Proxy statement: Proxy filing

2026-04-17T15:35:10.000Z - 4 months ago

GeoVax Labs price target lowered to $10 from $14 at Roth Capital

Apr 16, 2026, 8:00 AM EDT - 4 months ago

GeoVax Labs Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

GeoVax Labs Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

GeoVax Labs Proxy statement: Proxy filing

2026-04-16T10:11:41.000Z - 4 months ago

GeoVax Labs files to sell 1.27M shares of common stock for holders

2026-04-16T10:10:12.000Z - 4 months ago

GeoVax Labs files to sell 865,804 shares of common stock for holders

Apr 15, 2026, 7:00 AM EDT - 4 months ago

GeoVax Labs Annual report: Q4 2025

Apr 15, 2026, 7:00 AM EDT - 4 months ago

GeoVax Labs Earnings release: Q4 2025

2026-02-19T13:49:42.000Z - 6 months ago

GeoVax Labs downgraded to Hold from Buy at D. Boral Capital

Jan 13, 2026, 5:30 PM EST - 7 months ago

GeoVax Labs Transcript: Biotech Showcase 2026

2026-01-10T00:50:28.000Z - 7 months ago

Geovax Labs Inc trading halted, news pending

2025-12-12T22:30:17.000Z - 8 months ago

GeoVax Labs files to sell 18.29M units

Dec 12, 2025, 7:00 AM EST - 8 months ago

GeoVax Labs Registration statement: Registration Filing

Nov 13, 2025, 4:30 PM EST - 9 months ago

GeoVax Labs Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

GeoVax Labs Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

GeoVax Labs Quarterly report: Q3 2025

2025-10-17T20:45:13.000Z - 10 months ago

GeoVax Labs files to sell 11.9M shares of common stock for holders

Oct 17, 2025, 8:00 AM EDT - 10 months ago

GeoVax Labs Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

GeoVax Labs Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

GeoVax Labs Proxy statement: Proxy Filing

Sep 25, 2025, 3:55 PM EDT - 11 months ago

GeoVax Labs Transcript: Emerging Growth Conference 2025

Sep 8, 2025, 7:00 AM EDT - 1 year ago

GeoVax Labs Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 3:40 PM EDT - 1 year ago

GeoVax Labs Transcript: Emerging Growth Conference 85

2025-08-07T18:45:57.000Z - 1 year ago

HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q2 2025

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q2 2025

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Quarterly report: Q2 2025

2025-07-24T18:10:23.000Z - 1 year ago

Meet GeoVax Labs: Fly exclusive interview with CEO David Dodd

Jun 26, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Quarterly report: Q1 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Annual report: Q4 2024

Feb 19, 2025, 2:55 PM EST - 1 year ago

GeoVax Labs Transcript: Emerging Growth Conference 79

Jan 16, 2025, 2:35 PM EST - 1 year ago

GeoVax Labs Transcript: Emerging Growth Conference 78

Dec 9, 2024, 9:00 AM EST - 1 year ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Nov 26, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Oct 2, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 9, 2024, 7:00 AM EDT - 2 years ago

GeoVax Labs Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Sep 6, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Sep 3, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 8:59 PM EDT - 2 years ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 20, 2024, 8:09 AM EDT - 2 years ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 7:45 AM EDT - 2 years ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:00 AM EDT - 2 years ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

Aug 19, 2024, 7:30 AM EDT - 2 years ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 15, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 8:36 AM EDT - 2 years ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

Aug 8, 2024, 9:00 AM EDT - 2 years ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Aug 1, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Jul 31, 2024, 10:15 AM EDT - 2 years ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Jul 22, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings release: Q1 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Apr 4, 2024, 12:30 PM EDT - 2 years ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Apr 3, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 28, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 18, 2024, 5:30 PM EDT - 2 years ago

GeoVax Labs Transcript: Roth MKM 36th Annual ROTH Conference

Mar 12, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present at the 36th Annual Roth Conference

Mar 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 1, 2024, 7:00 AM EST - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Annual report: Q4 2023

Feb 29, 2024, 4:00 PM EST - 2 years ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 22, 2024, 9:00 AM EST - 2 years ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 19, 2024, 9:00 AM EST - 2 years ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 13, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Jan 29, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 8, 2024, 5:30 PM EST - 2 years ago

GeoVax Labs Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 9:00 AM EST - 2 years ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 4, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 3, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

Jan 2, 2024, 7:00 AM EST - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Dec 27, 2023, 9:00 AM EST - 2 years ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 19, 2023, 9:00 AM EST - 2 years ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Nov 30, 2023, 4:30 PM EST - 2 years ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 29, 2023, 9:00 AM EST - 2 years ago

GeoVax to Participate in Upcoming December Investor Events

Nov 28, 2023, 9:00 AM EST - 2 years ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 27, 2023, 7:00 AM EST - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Nov 17, 2023, 7:00 AM EST - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Nov 14, 2023, 9:00 AM EST - 3 years ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 8, 2023, 4:30 PM EST - 3 years ago

GeoVax Labs Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:30 PM EST - 3 years ago

GeoVax Labs Quarterly report: Q3 2023

Nov 8, 2023, 4:30 PM EST - 3 years ago

GeoVax Labs Earnings release: Q3 2023

Nov 8, 2023, 4:00 PM EST - 3 years ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 9:00 AM EDT - 3 years ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 25, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 24, 2023, 9:00 AM EDT - 3 years ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 9, 2023, 9:00 AM EDT - 3 years ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 3 years ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Sep 27, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Participate in Upcoming October Investor and Industry Events

Sep 20, 2023, 9:00 AM EDT - 3 years ago

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Sep 19, 2023, 9:00 AM EDT - 3 years ago

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Sep 12, 2023, 9:00 AM EDT - 3 years ago

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 11, 2023, 9:00 AM EDT - 3 years ago

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

Aug 31, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

Aug 28, 2023, 9:00 AM EDT - 3 years ago

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

Aug 10, 2023, 9:00 AM EDT - 3 years ago

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

reversal_trades Aug. 19 at 5:11 PM

1 · Reply

PennySearch Aug. 19 at 2:38 PM

0 · Reply

johnrivers0110 Aug. 19 at 2:12 PM

$CISS $GOVX $VRAX $MRNA $YJ Shorts are loading 🔺 especially on options stock mrna Trust me 🪡🪡🪡🩸🩸🩸 The FiB 🔺

1 · Reply

danceraka Aug. 19 at 2:05 PM

$CISS top watch, could go 10$-20$ like $PFSA $MRNA $FEMY $GOVX

0 · Reply

PennySearch Aug. 19 at 1:38 PM

0 · Reply

danceraka Aug. 19 at 1:26 PM

$CISS $FEMY $GOVX $VRAX

0 · Reply

CoffeeRocks Aug. 19 at 1:18 PM

$CODX $GOVX $VRAX $ISPC $MRNA Bio sector hot hot hot

0 · Reply

johnrivers0110 Aug. 19 at 1:01 PM

$CISS $GOVX $VRAX $MRNA $YJ

1 · Reply

RiseAboveAll752 Aug. 19 at 12:58 PM

$GOVX probably goes green

0 · Reply

RiseAboveAll752 Aug. 19 at 12:49 PM

$GOVX any reason?

0 · Reply

johnrivers0110 Aug. 19 at 12:38 PM

$CISS 🪡🩸 $GOVX 🪡🩸 $VRAX 🪡🩸 $MRNA 🪡🩸 $YJ 🐇🔺🚀🚀🚀

0 · Reply

danceraka Aug. 19 at 12:36 PM

$CISS $GOVX $VRAX $MRNA $YJ

0 · Reply

CoffeeRocks Aug. 19 at 12:27 PM

$VRAX $GOVX $ISPC $CODX

0 · Reply

KimberleyAnn Aug. 19 at 12:24 PM

$GOVX looking for a bounce here .58

1 · Reply

KingsPlay92 Aug. 19 at 12:16 PM

$GOVX be careful, shorts covering, news not very clear yet. momentum build up possible high risk, sidelines toxic financing but good pipeline ..

0 · Reply

MSG8898 Aug. 19 at 12:16 PM

$GOVX it was so obvious that they needed to raise cash for the quarter, and the premarket movement is consistent with an offering to be disclosed BMO.

0 · Reply

RiseAboveAll752 Aug. 19 at 12:11 PM

$GOVX

0 · Reply

TheUnmaker Aug. 19 at 12:04 PM

$GOVX

0 · Reply

TraderBuckNKY Aug. 19 at 12:01 PM

$GOVX 100's of us that were duped by this company and have incurred our largest losses ever.... I am compiling information from X, Reddit, and other forums-this one included, and making sure all of the individuals below are identified by all possible authorities and agencies and held accountable to the greatest of consequences that can be leveled against them. I wouldn't be surprised if subpoenas are on their way to being served to all of the referenced very soon. I will see that my Congress persons and Senators will receive a copy via email and paper correspondence. https://www.sec.gov/submit-tip-or-complaint/report-possible-securities-law-violations#:~:text=SEC.gov%20%7C%20Report%20Possible%20Securities%20Law%20Violations Never trust any of these individuals ever again: Mr. David Alan Dodd Chairman, President & CEO Dr. Mark J. Newman Ph.D. Chief Scientific Officer Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Medical Officer Mr. Mark W. Reynolds CPA CFO & Corporate Secretary Mr. Thomas O'Brien Vice President of Quality Systems & Compliance Mr. Jeffrey Welch Development & Manufacturing Dr. John W. Sharkey Ph.D. VP Bus. Dev.

0 · Reply

To_De_Moon Aug. 19 at 11:49 AM

$GOVX fuck David

0 · Reply

FormulaOneLover Aug. 19 at 11:49 AM

Made me a nice 4.5k$ profit on that. Big thanks 🙏 Would start Following @ElevenXProfits <~ if you like getting in them runners early 🔥 Might jump in to $NVAX $GOVX $WEN $RIME for runs

0 · Reply

Aatrader2475 Aug. 19 at 11:41 AM

$GOVX in with a few shares, let’s see where it goes 😉

0 · Reply

Market Cap	6.22M
Revenue (ttm)	3.95M
Net Income (ttm)	-24.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-632.66%
Debt to Equity Ratio	0.00

Volume	3,206,649
Avg Vol	2,079,406
Day's Range	N/A - N/A
Shares Out	30.06M
Stochastic %K	68%
Beta	3.67
Analysts	Strong Sell
Price Target	$9.62